A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Status:
Active, not recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of drugs (chemotherapy + Immunotherapy) as a
possible treatment for liposarcoma, leiomyosarcoma, or undifferentiated pleomorphic sarcoma
that has spread and has not responded to standard treatment.